Says: Solidifying path to double-digit growth by the end of the decade, with significant progress for patients with the approvals of ICOTYDE the first-and-only targeted oral peptide for plaque psoriasis, TECVAYLI plus DARZALEX FASPRO as early as second line for patients with relapsed/refractory multiple myeloma, VARIPULSE Pro in Europe with a new pulse sequence that is now 5 times faster, and TECNIS PureSee Intraocular Lens for U.S. Cataract Patients. company announces planned Enterprise Business Review for December 8, 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- These Are the Stocks Reporting Earnings Today – April 14, 2026
- Notable companies reporting before tomorrow’s open
- Polymarket Odds: Will BLK, JPM, JNJ Beat Earnings Tomorrow?
- Ahead of Q1 Earnings, What Do Analysts Think About Johnson & Johnson Stock (JNJ)?
- Options Volatility and Implied Earnings Moves This Week, April 13 – April 17, 2026